Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Agios Pharmaceuticals announced that the Phase 2 trial of tebapivat in sickle cell disease did not establish a differentiated profile compared to the PK activator class, leading to the decision not to advance the program. The trial met primary endpoints for hemoglobin response across dose levels (43.8%, 47.1%, and 29.4% for 2.5 mg, 5.0 mg, and 7.5 mg doses, respectively) but failed to show sufficient differentiation versus the 33.3% placebo response and existing mechanisms.
Key figures
- Pdufa date
- November 1, 2026
- Participants
- 59
- Response rate 2 5mg
- 43.8%
- Response rate 5 0mg
- 47.1%
- Response rate 7 5mg
- 29.4%
- Response rate placebo
- 33.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.